Zhejiang Hisun Pharmaceutical's subsidiary's preparation product Fluorouracil Injection has been approved by the US FDA.

Zhejiang Hisun Pharmaceutical (600267.SH) announced recently that its wholly-owned subsidiary Zhejiang Hisun Pharmaceutical (Hangzhou) Co., Ltd. (referred to as "Hisun Hangzhou Company") has received notification from the US Food and Drug Administration (FDA) that the abbreviated new drug application (ANDA) for its Fludarabine Phosphate Injection has been approved. This means that Hisun Hangzhou Company can now sell the product in the US market. Fludarabine Phosphate Injection is a nucleoside metabolic inhibitor indicated for use as a component of combination therapy for the treatment of adult chronic lymphocytic leukemia (CLL), and for the treatment of adult patients with CLL who have not responded to at least one prior therapy containing an alkylating agent, or whose disease has progressed during treatment.